Omnicell, Inc. $OMCL Shares Bought by Cubist Systematic Strategies LLC

Key Points

• Cubist Systematic Strategies LLC increased its position in Omnicell, Inc. by 56.8% during the first quarter, acquiring an additional 99,406 shares to hold a total value of approximately $9.60 million.
• Omnicell's quarterly earnings topped estimates with $0.45 earnings per share, beating the consensus of $0.30, and the company reported a 5% revenue increase year-over-year.
• Analysts have set a consensus price target of $46.71 for Omnicell, with several institutions adjusting their ratings, indicating a shift in sentiment towards a more cautious outlook.

Cubist Systematic Strategies LLC increased its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 56.8% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 274,489 shares of the company's stock after purchasing an additional 99,406 shares during the period. Cubist Systematic Strategies LLC owned approximately 0.59% of Omnicell worth $9,596,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its position in Omnicell by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 244,644 shares of the company's stock valued at $8,553,000 after buying an additional 6,288 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Omnicell in the 1st quarter valued at approximately $2,073,000. Jane Street Group LLC boosted its position in Omnicell by 7.4% in the 4th quarter. Jane Street Group LLC now owns 54,282 shares of the company's stock valued at $2,417,000 after buying an additional 3,725 shares during the period. GSA Capital Partners LLP purchased a new position in Omnicell in the 1st quarter valued at approximately $901,000. Finally, XTX Topco Ltd boosted its position in Omnicell by 316.1% in the 1st quarter. XTX Topco Ltd now owns 30,295 shares of the company's stock valued at $1,059,000 after buying an additional 23,015 shares during the period. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Stock Down 3.0%

NASDAQ:OMCL traded down $1.01 during midday trading on Friday, hitting $32.11. 423,987 shares of the company were exchanged, compared to its average volume of 540,095. The company has a fifty day simple moving average of $30.44 and a 200 day simple moving average of $31.37. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.74. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1.47 billion, a PE ratio of 64.22, a price-to-earnings-growth ratio of 7.23 and a beta of 0.82.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The firm had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. During the same period last year, the business earned $0.51 EPS. Omnicell's revenue for the quarter was up 5.0% compared to the same quarter last year. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, equities analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on OMCL shares. Wells Fargo & Company raised their price target on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research report on Monday, July 21st. Piper Sandler decreased their price target on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 11th. Wall Street Zen cut shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Bank of America raised their price objective on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, May 23rd. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $46.71.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.